Autres langues Pharvaris N.V.

Actions

PHVS

NL00150005Y4

Temps réel estimé Cboe BZX Autres places de cotation 21:20:25 07/06/2024			Varia. 5j.	Varia. 1 janv.
16,06 ^USD	-4,49 %		-15,27 %	-42,73 %

04/06	Pharvaris souligne les propriétés du deucrictibant lors de présentations de données à des congrès récents	CI
09/05	PHARVARIS N.V. : Wedbush toujours positif	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses	04/06
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses	04/06
Pharvaris N : Development of Kallikrein Kinin System Biomarker Assays to Investigate Bradykinin mediated Diseases	02/06
Pharvaris N : Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema	22/05
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses	13/05
Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update	08/05
Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024	08/05
Pharvaris Files Mixed Shelf	12/04
Pharvaris Narrows Q4 Net Loss; Hires New CFO	10/04
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	10/04
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10/04
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer	10/04
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference	04/04
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18/03
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses	18/03
Pharvaris N : Poster	15/03
Pharvaris N : EGM Meeting Minutes	12/03
Pharvaris N : Results of Extraordinary General Meeting of Shareholders - Form 6-K	06/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pharvaris N.V.

Actions

PHVS

NL00150005Y4

Autres langues

Filtres